Commonwealth Bank of Australia cut its holdings in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 37.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,850 shares of the company’s stock after selling 9,430 shares during the quarter. Commonwealth Bank of Australia’s holdings in Endo International were worth $147,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ENDP. Xact Kapitalforvaltning AB raised its stake in Endo International by 44.5% in the first quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock valued at $174,000 after buying an additional 9,000 shares during the last quarter. Neuburgh Advisers LLC raised its stake in Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock valued at $215,000 after buying an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC raised its stake in Endo International by 83.9% in the first quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock valued at $245,000 after buying an additional 18,800 shares during the last quarter. Tyers Asset Management LLC raised its stake in Endo International by 84.2% in the first quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock valued at $274,000 after buying an additional 21,084 shares during the last quarter. Finally, Flinton Capital Management LLC raised its stake in Endo International by 84.2% in the first quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock valued at $333,000 after buying an additional 25,602 shares during the last quarter. Institutional investors own 98.43% of the company’s stock.

A number of equities research analysts have commented on ENDP shares. Deutsche Bank set a $11.00 price target on Endo International and gave the company a “buy” rating in a research note on Wednesday, July 18th. Goldman Sachs Group upgraded Endo International from a “sell” rating to a “neutral” rating and increased their price target for the company from $14.00 to $15.00 in a research note on Tuesday. BidaskClub upgraded Endo International from a “sell” rating to a “hold” rating in a research note on Friday, June 8th. TheStreet upgraded Endo International from a “d” rating to a “c-” rating in a research note on Monday, August 20th. Finally, ValuEngine cut Endo International from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Endo International has an average rating of “Hold” and an average price target of $14.07.

In related news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total transaction of $414,576.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.80% of the stock is owned by company insiders.

Shares of ENDP stock opened at $16.05 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.91 and a debt-to-equity ratio of -132.64. The stock has a market capitalization of $3.63 billion, a PE ratio of 5.22, a PEG ratio of 3.12 and a beta of 0.74. Endo International PLC has a fifty-two week low of $5.27 and a fifty-two week high of $17.46.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.22. The business had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The company’s revenue was down 18.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.93 earnings per share. research analysts anticipate that Endo International PLC will post 2.6 EPS for the current year.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: How Short Selling Works

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.